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Background: Chronically increased intestinal iron uptake in genetic hemochromatosis (HC) may cause organ failure.
Whilst iron loading from blood transfusions may cause dilated cardiomyopathy in conditions such as thalassemia,
the in-vivo prevalence of myocardial siderosis in HC is unclear, and its relation to left ventricular (LV) dysfunction is
controversial. Most previous data on myocardial siderosis in HC has come from post-mortem studies.
Methods: Cardiovascular magnetic resonance (CMR) was performed at first presentation of 41 HC patients
(58.9 ±14.1 years) to measure myocardial iron and left ventricular (LV) ejection fraction (EF).
Results: In 31 patients (genetically confirmed HFE-HC), the HFE genotype was C282Y/C282Y (n = 30) and C282Y/
H63D (n = 1). Patients with other genotypes (n = 10) were labeled genetically unconfirmed HC. Of the genetically
confirmed HFE-HC patients, 6 (19%) had myocardial siderosis (T2* <20 ms). Of these, 5 (83%) had heart failure and
reduced LVEF which was correlated to the severity of siderosis (R2 0.57, p = 0.049). Two patients had follow-up scans
and both had marked improvements in T2* and LVEF following venesection. Myocardial siderosis was present in 6/
18 (33%) of patients with presenting ferritin ≥1000 μg/L at diagnosis but in 0/13 (0%) patients with ferritin <1000
μg/L (p = 0.028). Overall however, the relation between myocardial siderosis and ferritin was weak (R2 0.20, p =
0.011). In the 10 genetically unconfirmed HC patients, 1 patient had mild myocardial siderosis but normal EF. Of all
31 patients, 4 had low LVEF from other identifiable causes without myocardial siderosis.
Conclusion: Myocardial siderosis was present in 33% of newly presenting genetically confirmed HFE-HC patients
with ferritin >1000 μg/L, and was the commonest cause of reduced LVEF. Heart failure due to myocardial siderosis
was only found in these HFE-HC patients, and was reversible with venesection. Myocardial iron was normal in
patients with other causes of LV dysfunction.
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Genetic hemochromatosis (HC) is a common disorder in
the Caucasian population, with a prevalence of 2–5 per
thousand [1]. In adults, the C282Y HFE protein variant
(tyrosine substitution for cysteine at amino acid 282) is the
most important variant associated with HC, and most adult
HC patients are C282Y homozygotes. The frequency of
C282Y heterozygotes in the North American and European
population is 0.9% and 9.2% respectively. In addition, there
is the H63D HFE protein variant (aspartate substitution for* Correspondence: D.Pennell@imperial.ac.uk
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reproduction in any medium, provided the orhistidine at amino acid 63) which is associated with HC in
C282Y/H63D compound heterozygotes [2], and this muta-
tion has a heterozygote frequency in North America of 23%
and 22% in Europe. An S65C mutation (cysteine substitu-
tion for serine at amino acid 65) has recently been suggested
to be associated with a milder form of HC and carrier fre-
quencies in Caucasian population are 1-4% [3,4]. Biochem-
ical penetrance, with raised iron parameters such as ferritin
and transferrin saturation, is 38-76% [5], but clinical pene-
trance is lower at 2-38% in men and 1-10% in women [6,7].
The risk of developing overt disease is modulated by other
factors including alcohol, inflammation and viral infections
[8,9]. Abnormal iron handling with HFE gene and other
rarer genetic mutations causing HC, appears to be mediated
via inappropriately low production of hepcidin, which is aral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Carpenter et al. Journal of Cardiovascular Magnetic Resonance 2013, 15:24 Page 2 of 9
http://www.jcmr-online.com/content/15/1/24master iron regulator [10]. This results in augmented iron
export by ferroportin from duodenal enterocytes and retic-
uloendothelial macrophages, which chronically increases
iron absorption from the duodenum and upper intestine,
raises plasma iron levels and causes iron accumulation in
the body [11].
A reported complication of excess iron deposition in
HC is the development of dilated cardiomyopathy (DCM)
[12]. Cardiovascular magnetic resonance (CMR) has been
used to assess myocardial iron deposition and DCM in
patients with thalassemia using the relaxation parameters
T2* and T2, but T2* is in wider clinical use because of
ease of acquisition and implementation [13,14]. Heart T2*
falls with increasing iron loading [15,16], with the normal
myocardial T2* being approximately 40 ms. Myocardial
iron overload is present when T2* <20 ms [13], and heart
failure usually only occurs when myocardial T2* is <10 ms
[17]. However, while myocardial siderosis and DCM have
been directly linked in thalassemia, and reversal of left
ventricular (LV) dysfunction demonstrated with iron
chelation [18], there is scant data on in-vivo myocardial
iron loading in HC, and most knowledge is based on
highly selected autopsy studies [19], with considerable
controversy over the causation of LV dysfunction. There-
fore, in this study we investigated the hypothesis that LV
dysfunction was related to myocardial siderosis in HC.
Methods
We prospectively studied 41 patients by CMR at the time of
their first presentation with a clinical diagnosis of HC. In all
patients, the clinical diagnosis was made in specialist HC
clinics, and was based on accepted criteria, including charac-
teristic clinical findings, abnormal serum parameters of iron
metabolism (serum ferritin, serum iron, transferrin iron sat-
uration) and HFE mutation analysis [20]. Genetic testing
for the C282Y and H63D HFE mutations was performed
in all patients. Patients had serum ferritin values taken at
initial clinical presentation (and before commencing treat-
ment with venesection in confirmed cases of HC) and this
value was used as the presentation ferritin for compari-
sons with myocardial T2* and LV function.
CMR was performed on a 1.5T scanner (Siemens Sonata,
Erlangen, Germany) with measurement of T2* of the heart
and liver, and LV function, volumes and mass. In brief, the
myocardial T2* images were acquired using a single
10mm-thick short-axis mid-ventricular slice of the LV with
8 echo times (2.6 to 16.7 ms, with 2.02 ms increment) in a
single breath-hold [21]. A similar technique was used for
the liver T2* acquisition, but with shorter echo times
(0.9 ms to 16.0 ms, with 1.34 ms increment). Ventricular
volumes, mass, and function were determined with the
use of steady state free precession cines, with contiguous
short-axis slices from base to apex [22]. For myocardial
T2* measurement, a full thickness region of interest(ROI) was measured in the septum, distant from the
cardiac veins and lungs to avoid susceptibility artefacts. A
large ROI away from vessels was likewise analyzed for the
liver. To derive T2*, the data was fitted with an exponential
equation and a truncation model [23,24]. All myocardial
T2* analyses were performed using Thalassemia-Tools, a
plug-in of CMRtools (Cardiovascular Imaging Solutions,
London, UK). Complete ventricular volumetric and mass
analyses were also performed using CMRtools [22]. All data
analysis was performed by a single experienced operator.
The reproducibility of T2* and volume measurements have
been reported previously [21,25].
Statistical analysis of normal variables is shown as mean ±
standard deviation (SD) for data with a normal distribution,
and median [Q1, Q3] for data with a non-normal distribu-
tion. Linear regression analysis was performed relating
ejection fraction to myocardial T2*, and a p-value of <0.05
was considered statistically significant. Iron concentrations
for liver and heart were calculated from the papers by
Wood [26] and Carpenter [16]. This study was approved by
the institutional Research Ethics Committee and all patients
gave informed written consent. The study was carried out
in accordance with the Declaration of Helsinki.
Results
The homozygous C282Y/C282Y genotype was found in 30
patients with the compound heterozygous C282Y/H63D
genotype found in 1 patient. These 31 patients were labeled
as genetically confirmed HFE-HC [27]. The remaining 10
patients had other genotypes and were labeled as genetically
unconfirmed HC (C282Y/wt in 5; H63D/H63D in 4; H63D/
wt in 1). Further genetic testing for rare mutations in HFE
and other iron handling genes was not performed. The
baseline characteristics of the genetically confirmed HFE-
HC and genetically unconfirmed HC patients are shown in
Tables 1 and 2 respectively. The mean age of all 41 patients
was 58.9 ±14.1 years indicating a middle-age to elderly
population, and there was a strong male preponderance
(73.1%). All patients had a raised ferritin level at presenta-
tion, and in addition the iron binding saturation or iron
levels were also significantly raised. Median liver T2* was
markedly reduced indicating liver iron loading with median
liver iron concentration estimated at 8.7 mg/g dw
[3.7, 18.3] in genetically confirmed HFE-HC patients, and
1.8 mg/g dw [1.3, 4.2] in genetically unconfirmed patients.
Six patients underwent liver biopsy due to abnormal liver
function test results, all of which showed fibrosis with
cirrhotic change seen in three of the six. The median LV
volumes, mass and EF were normal for the whole patient
cohort, but were abnormal in the individual patients
with impaired LV function.
The results of the myocardial T2* scan at presentation
of the patients in relation to the LV ejection fraction
(EF) are shown in Figure 1 for the genetically confirmed
Table 1 Genetically confirmed HFE-HC patient group: patient characteristics at time of CMR scan
Number of patients 31
Male/Female 25/6
Age (years): mean [SD] 58.8 [13.6]
Weight (kg): mean [SD] 80.8 [14.5]
Height (cm): mean [SD] 173 [11.8]
Race Caucasian 31
Genetic mutation analysis: N (%) C282Y/C282Y 30 (97%)
C282Y/H63D 1 (3%)
Presentation ferritin (μg/L): median [Q1, Q3];
Normal 30-400
1286 [639, 2772]
Iron (μmol/L): mean [SD]; Normal 9-30 43.5 [12.7]
Iron binding saturation (%): mean [SD]; Normal 25-50 67.5 [19.8]
Hb (g/dL): mean [SD]; Normal 13-15 13.6 [1.4]
Liver T2* (ms): median [Q1, Q3]; Normal 26.7 ±4.2 ms 3.0 [1.4, 7.3]
Liver iron concentration (mg/g dw): median [Q1, Q3] 8.7 [3.7, 18.3]
LV EDV/BSA (mL/m2): median [Q1, Q3]; Normal 60-95 77 [64, 88]
LV ESV/BSA (mL/m2): median [Q1, Q3]; Normal 16-36 24 [20, 29]
LV EF (%): median [Q1, Q3]; Normal 58-76 70 [59, 73]
LV mass/BSA (g/m2): median [Q1, Q3]; Normal 53-84 70 [58, 90]
Cardiac T2* (ms): median [Q1, Q3]; Normal 40 ms 34.8 [25.4, 40.1]
Cardiac iron concentration (mg/g dw):
median [Q1, Q3]
0.59 [0.50, 0.87]
(BSA body surface area, EDV end-diastolic volume, EF ejection fraction, ESV end-systolic volume, Hb Hemoglobin, LV left ventricle, SD standard deviation, Q1 lower
quartile, Q3 upper quartile). Normal values from Westwood [21], and Maceira [22].
Carpenter et al. Journal of Cardiovascular Magnetic Resonance 2013, 15:24 Page 3 of 9
http://www.jcmr-online.com/content/15/1/24HFE-HC patients, and Figure 2 for the genetically
unconfirmed patients. Median time from clinical diagnosis
to CMR T2* scan was 3.0 [0.25, 10.8] months, and from
start of venesection to CMR scan was 0 [0, 3] months. Of
the 31 genetically confirmed HFE-HC patients, 23 (74%)
patients had both normal myocardial T2* and LV function.
Six (19%) patients had a myocardial T2* below 20 ms
indicating myocardial siderosis, and of these, 5 (83%)
also had LV dysfunction, all of whom had a history of
heart failure. All patients with myocardial siderosis had
a serum ferritin at presentation >1300 ng/L (sensitivity
100%, specificity 64.0%). Two other patients had normal
myocardial T2* (>20 ms) with reduced LVEF. Both these
patients had a prior definitive diagnosis and documented
clinical history which explained the LV dysfunction,
namely chronic substance abuse with drugs and alcohol
[1] and previous anterior myocardial infarction with
severe three vessel disease at coronary angiography [1]. Of
the 5 patients with recent heart failure who did not have
an alternative explanation for their LV dysfunction, the
investigations showed: serum ferritin 3000 [1890, 4901]
μg/L, myocardial T2* 7.4 [6.7, 9.8] ms, liver T2* 1.2 [1.2,1.4]
ms, LVEDV 236 ±70 ml, LVESV 161 ±56 ml, EF 35 ±5%
and LV mass 161 ±56 g.In order to examine whether there were any predictive
measures of myocardial iron loading, regression analysis
was performed of myocardial T2* against presentation
serum ferritin, age and liver iron (as measured by liver T2*)
as shown in Figure 3. There was a weak relation between
increasing myocardial siderosis and increasing presentation
serum ferritin (R2 0.20, p = 0.011). Dividing serum
ferritin by age yielded a slightly stronger correlation
(R2 0.29, p = 0.0017) against myocardial T2* than for ferritin
alone. There were no statistically significant relations found
for the regression of age (R2 0.027, p = 0.38), and liver iron
as measured by liver T2* (R2 0.020, p = 0.44). Similarly, no
correlation was found between myocardial siderosis and
liver T2* divided by age (equivalent of the hepatic iron
index: R2 0.015, p = 0.51). Regression analysis showed no
relation between myocardial T2* and EF for normal
values of myocardial iron (T2* >20 ms; R2 0.001; p =
0.85). However, for those patients with myocardial
siderosis (T2* <20 ms), the relation between myocardial
T2* and EF was significant (R2 0.57; p = 0.049). All C282Y
homozygotes with myocardial siderosis had liver T2* <3 ms
(sensitivity 100%, specificity 64.0%).
Of the 10 genetically unconfirmed HC patients, 7 (70%)
patients had both normal myocardial T2* and LV function.
Table 2 Genetically unconfirmed HC patient group: patient characteristics at time of CMR scan
Number of patients 10
Male/Female 6/4
Age (years): mean [SD] 60.0 [15.9]
Weight (kg): mean [SD] 70.4 [16.4]
Height (cm): mean [SD] 175 [10.6]
Race Caucasian 10
Genetic mutation analysis: N (%) C282Y/wt 5 (50%)
H63D/H63D 4 (40%)
H63D/wt 1 (10%)
Presentation ferritin (μg/L): median [Q1, Q3];
Normal 30-400
920 [660, 1912]
Iron (μmol/L): mean [SD]; Normal 9-30 34.0 [11.6]
Iron binding saturation (%): mean [SD]; Normal 25-50 64.8 [18.7]
Hb (g/dL): mean [SD]; Normal 13-15 13.6 [1.4]
Liver T2* (ms): median [Q1, Q3]; Normal 26.7 ±4.2 ms 16.4 [6.3, 23.0]
Liver iron concentration (mg/g dw): median [Q1, Q3] 1.8 [1.3, 4.2]
LV EDV/BSA (mL/m2): median [Q1, Q3]; Normal 60-95 79 [64, 83]
LV ESV/BSA (mL/m2): median [Q1, Q3]; Normal 16-36 22 [19, 38]
LV EF (%): median [Q1, Q3]; Normal 58-76 68 [63, 72]
LV mass/BSA (g/m2): median [Q1, Q3]; Normal 53-84 80 [74, 89]
Cardiac T2* (ms): median [Q1, Q3]; Normal 40 ms 30.9 [26.8, 34.5]
Cardiac iron concentration (mg/g dw): median [Q1, Q3] 0.68 [0.60, 0.81]
Abbreviations: wt - wild type; other abbreviations as Table 1.
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mild myocardial siderosis) with a serum ferritin of 840 μg/L
at presentation but normal LV function. Two other patients
had normal myocardial T2* (>20 ms) with reduced LV EF.
Both these patients had a prior definitive diagnosis and
documented clinical history which fully explained the LV
dysfunction, namely a) non-Hodgkins lymphoma with 3
years of chemotherapy and bone marrow transplantation
with whole body radiation and b) myocarditis with mid-wall
LV fibrosis shown with late gadolinium enhancement CMR.
Late gadolinium enhancement (LGE) imaging was not
performed routinely in the patient cohort. However 7
patients had LGE imaging for clinical indications. Of 6
patients with genetically confirmed HFE-HC, two patients
had LGE, the first of which was the patient with the
documented anteroseptal myocardial infarction. The other
patient had heart failure and low T2* (Figure 1), with mid-
wall fibrosis (myocardial T2* 9.8 ms with a severely dilated
ventricle and LV EF of 29%) and no prior history of cardiac
pathology. In the patients with genetically unconfirmed HC,
only 1 had LGE (the patient with a documented prior
history of myocarditis), with mid-wall fibrosis (Figure 2).
Two of the 5 patients with genetically confirmed HFE-HC
who presented in heart failure were rescanned after vene-
section (Figure 4). Both repeat scans showed a considerable
improvement in the LV EF and myocardial T2*.Discussion
In genetic hemochromatosis (HC), the intestinal absorption
of iron is high and multi-organ iron overload with organ
failure may occur over a period of decades. Myocardial iron
loading is well known as a possible complication, but as far
as we are aware, this is the first study of myocardial iron
loading in newly presenting patients with possible HC. This
is now feasible because of the non-invasive nature of T2*
CMR as myocardial biopsy to assess iron loading is
restricted to highly selected cases. Analysis of possible
predictors of myocardial iron loading as assessed by T2*
showed that all genetically confirmed HFE-HC patients with
myocardial siderosis had a presenting serum ferritin value
of >1000 μg/L, a value that is also associated with an
increased risk of developing liver pathology. Above this
threshold, myocardial siderosis was present in 6/18 (33%)
patients compared with 0/13 (0%) patients with presenting
ferritin values <1000 µg/L (p=0.028). Whilst the lowest
serum ferritin measured in genetically confirmed HFE-HC
patients with myocardial siderosis was 1300 ug/L, a more
conservative threshold of 1000 ug/L would appear to be a
more appropriate level for clinical practice, because the pa-
tient with the lowest serum ferritin of 1300 ug/L had a
myocardial T2* of 7.4 ms indicating severe iron loading.
The limited sample size of this study may therefore not
have identified patients with a milder degree of myocardial
Figure 1 Relation between myocardial T2* and ejection fraction in genetically confirmed HFE-HC patients. The 2 patients with LV
dysfunction and normal myocardial iron (T2* >20 ms) had clear alternative diagnoses for the impaired ejection fraction (as shown). The relation
between myocardial T2* and LVEF is only significant when myocardial iron overload is present.
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lower serum ferritin threshold would not miss patients with
myocardial siderosis, it would seem reasonable on this basis
of the data presented here to recommend T2* CMR on all
confirmed HC patients presenting with a serum ferritin
>1000 µg/L.
Another consideration in HC, is the development of
heart failure. Dilated cardiomyopathy (DCM) is well
recorded in HC, and reports recommend that serum
ferritin should be measured in newly presenting cases of
DCM [28]. In thalassemia, there is unequivocal evidence
showing that iron causes the LV dysfunction, becauseFigure 2 Relation between myocardial T2* and ejection fraction in ge
dysfunction and normal myocardial iron (T2* >20 ms) had clear alternativesevere myocardial siderosis is present in patients with
heart failure [16,17], and LV dysfunction is reversible with
iron chelation during which time the myocardial siderosis
improves [18,29-31]. The relation between myocardial
siderosis and LV dysfunction has never been shown in-
vivo in HC. In addition the cause of LV dysfunction in HC
is controversial. Apart from myocardial iron deposition,
there have been 3 alternative proposed explanations.
The first alternative explanation for LV dysfunction in
HC is that myocardial damage results from coronary
artery disease (CAD) exacerbated by chronically increased
iron levels. A correlation has been shown between highnetically unconfirmed HC patients. The 2 patients with LV









































































Figure 3 Relation between myocardial T2* and potential
predictors of myocardial iron loading in the genetically confirmed
HFE-HC patients: a) presentation serum ferritin (p = 0.011), b)
age (p = 0.38), c) liver iron as measured by liver T2* (p = 0.44).
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infarction, with a plausible mechanism of augmented lipid
peroxidation [32]. Iron could also promote atherogenesis
and post-ischemic myocardial injury and perhaps arrhyth-
mias [33]. Supportive data for this view includes the lower
incidence of coronary artery disease in women due to
lower iron levels through life resulting from menstruation,
and the increased incidence of CAD in a cohort of 2,873
Framingham women who had a natural or surgical meno-
pause. However, others have not found a relation between
storage iron and myocardial infarction [34]. An additional
issue in HC is the possible interaction of the genetic
abnormality and risk of coronary disease. There has
been a report of an increased risk of myocardial infarction
in men who are carriers of the HFE C282Y mutation,
which may suggest that that the mutation might con-
fer an increased risk of CAD [35]. A study of 20,555
post menopausal women also showed that women
with CAD risk factors who were heterozygous for the
HFE C282Y mutation developed more CAD in com-
parison with matched women with homozygous wild-
type HFE genotype [36]. These studies suggest that
the HFE mutation in itself may promote CAD that
could explain LV dysfunction.
The second alternative hypothesis is that the HFE gene
is directly causative for DCM, with an increased
frequency of the H63D mutation, but not the C282Y
mutation [37]. The survival rate in this study was similar
between the H63D carriers and non-carriers, but patients
with the C282Y mutation had a shorter duration of illness
before presentation, less LV volume dilatation and better
fractional shortening. This is somewhat surprising because
H63D has less of an effect on iron metabolism compared
with C282Y, which suggests that factors other than just
direct iron damage may predispose the patients to DCM.
However, other studies have not observed differences in
frequency between the DCM population with C282Y or
H63D mutations and non carriers [3], including the
CARDIGENE study in which no difference in HFE carrier
frequency was found between DCM patients and controls
[38]. If genetic predisposition is a cause of DCM in HC
[39,40], there is limited understanding of the mechanism.
A third explanation for LV dysfunction in HC is the
possibility of predisposition to autoimmune disease, as
the HFE gene is located close to the human leucocyte
antigen (HLA) locus. An autoimmune mechanism for
DCM has been suggested in subjects where there is an
abnormal response of the immune system to different
insults [37,41]. The low CD8+ T cell count in DCM
patients have been stated to support this hypothesis [41].
Therefore the four possible explanations for the LV
dysfunction in HC, either alone or in concert, remain
unresolved in relative importance. Our data from the
current study substantially clarify this debate. We found
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Figure 4 Examples of CMR scans from newly presenting patients with C282Y homozygous hemochromatosis and heart failure. a) 54 year-old
male with presenting myocardial T2* of 5.4 ms and LVEF of 36%. When rescanned 31 months later after venesection, the cardiac T2* had improved to
15.7 ms, and the LVEF to 65%. b) 59 year-old female with presenting cardiac T2* of 7.4 ms and LVEF of 35%. Rescanning 19 months later after
venesection showed improvement in T2* to 23.6 ms and LVEF to 61%. In both cases, venesection resulted in considerable improvement in iron loading
and cardiac function. Top row: horizontal long axis, middle row: mid-ventricular short axis, bottom row: vertical long axis.
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LV dysfunction. The first group were those patients with
myocardial siderosis (T2* <20 ms). The prevalence of
myocardial siderosis at first presentation of HC in
patients with serum ferritin >1000 ug/L was high at 33%.
Of these genetically confirmed HFE-HC patients with
myocardial siderosis, 83% had associated LV dysfunction
and all had heart failure. Myocardial siderosis was thereforethe commonest cause of LV dysfunction. A second
group of genetically confirmed HFE-HC patients in our
study with LV dysfunction had no myocardial iron
loading but had well documented existing causes, namely
anterior myocardial infarction, or substance abuse. Two
other cases of LV dysfunction occurred in the genetically
unconfirmed HC patients, which were caused by myocar-
ditis or cancer treatment.
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not common in this predominantly middle-aged to
elderly population, and there was little evidence of
unexplained cardiomyopathy to support the other possible
etiologies (direct genetic effects or autoimmunity) which
have been previously postulated for LV dysfunction in HC.
This indicates that myocardial T2* is required to definitively
diagnose myocardial siderosis in newly presenting patients
with HC. This has the added merit in patients with
impaired or borderline LV function of confidently
excluding myocardial iron loading as the cause where
possible alternative diagnoses are known or suspected,
such as coronary disease or the prior use of cardiotoxic
drugs, as long-term specific treatment for the cause of LV
dysfunction is required.
The limitations of this research include the relatively
small sample size, which relates to the difficulty of
recruiting newly-presenting HC patients. Late gadolin-
ium enhancement was performed only in 7 patients in
whom there was a possible history of cardiac disease and
therefore there is limited data on cardiac fibrosis. Of the
5 genetically confirmed HFE-HC patients who presented
in heart failure with a low cardiac T2*, 2 had LGE
imaging with one having no LGE and one having mid-wall
LGE with no prior history of cardiac pathology. It is not
clear whether the latter patient’s LGE could be attributed
to myocardial siderosis. Only 2 patients were referred to
be rescanned for clinical reasons, and therefore the
response of cardiac T2* to venesection is not known for
all patients. However, in the 2 that were rescanned, there
was an impressive improvement in myocardial T2* and EF
with venesection over nearly 3 years in both cases. We did
not test for nutritional factors including thiamine and
vitamin D [42,43], which may exacerbate heart failure in
other iron overload conditions such as thalassemia major,
although there is little evidence for derangement in HC.
The patient cohort comprised of patients with a clinical
diagnosis of HC and subsequent genetic analysis was only
able to confirm the genetic diagnosis in 31 of 41 patients
studied. We present the data of these 31 genetically con-
firmed HFE-HC patients separately to ensure comparability
with future studies. Further detailed genetic analysis of the
10 genetically unconfirmed HC patients was not available.
Conclusion
In conclusion, our data show myocardial siderosis is com-
mon in HFE-HC patients (33%) presenting with iron over-
load (serum ferritin >1000 μg/L), a value associated with
increased risk of liver damage in HFE-HC, and is uncom-
mon below this threshold. Myocardial siderosis was the
commonest cause of LV dysfunction, but some cases of
heart failure were attributable to other causes as a result of
the age of the population. There is little evidence for excess
coronary artery disease, or a direct genetic or autoimmunecause for cardiomyopathy. In two cases of patients with
heart failure and myocardial siderosis, we demonstrated a
marked improvement in left ventricular function in parallel
with an improvement in T2* following venesection. There-
fore T2* CMR is not only useful for demonstrating the
myocardial siderosis, but also in differentiating it from
other causes of LV dysfunction which have different
treatments and in monitoring the response to therapy.
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